Dr. Mali’s Top 5 Predictions for 2018

Dr. Josh Mali, Retina, Uncategorized

This is an article by Dr. Joshua Mali published by Ophthalmology Times. 1). Aflibercept and ranibizumab utilization will continue to soar to new heights in 2018. The success of aflibercept (Eylea, Regeneron Pharmaceuticals) and ranibizumab (Lucentis, Genentech/Roche) injections will definitely continue in 2018. Regeneron just recently reported fourth-quarter 2017 sales of its flagship product, aflibercept, […]

Read More